MedElevator
Войти в исследования Respiratory medicine · 2026
Incidence, mortality and risk factors in COVID-19-associated pulmonary aspergillosis (CAPA): an umbrella review and meta-meta-analyses (2020-2025).
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
de Victoria Carazo Javier Martínez, Guirao Arrabal Emilio, Montero-Alonso Miguel Ángel, Yuste Ossorio María Eugenia, García García Federico, Hernández Quero José
Аннотация
INTRODUCTION: COVID-19-associated pulmonary aspergillosis (CAPA) has emerged as a severe and potentially underrecognised complication in patients with SARS-CoV-2 infection, particularly in intensive care units (ICUs). Existing reviews show substantial heterogeneity in diagnostic criteria, incidence estimates, and reported risk factors, limiting reliable interpretation of the overall evidence base.
MATERIALS AND METHODS: this umbrella review synthesised systematic reviews and meta-analyses published between 2020 and 2025 to clarify the incidence, mortality, and risk factors associated with CAPA. Searches were conducted in PubMed and Scopus. Eligibility was restricted to articles published in English and Spanish. Pooled estimates were re-calculated through a dedicated meta-metaanalysis.
RESULTS: sixteen reviews met the inclusion criteria, nine of them with meta-analysis. The pooled incidence among critically ill patients was 11.3% (95% CI 9.2-13.9), strongly influenced by diagnostic variability and the limited use of bronchoalveolar lavage during the pandemic. Overall mortality reached 51.6% (IQR 48.3-54.5), and CAPA tripled the risk of death compared with non-CAPA patients (OR 3.08; 95% CI 2.73-3.49). Consistent risk factors identified across meta-analyses included advanced age (OR 1.05 per year), chronic obstructive pulmonary disease (OR 1.98), type 2 diabetes mellitus (OR 1.25), systemic corticosteroid exposure (OR 1.72), and IL-6 inhibitors (OR 2.32).
DISCUSSION AND CONCLUSIONS: the marked heterogeneity observed across studies highlights the urgent need for harmonised and clinically applicable diagnostic criteria. CAPA remains an underdiagnosed condition associated with substantial mortality, underscoring the importance of early recognition strategies and improved diagnostic availability to guide timely management in high-risk patients.
MATERIALS AND METHODS: this umbrella review synthesised systematic reviews and meta-analyses published between 2020 and 2025 to clarify the incidence, mortality, and risk factors associated with CAPA. Searches were conducted in PubMed and Scopus. Eligibility was restricted to articles published in English and Spanish. Pooled estimates were re-calculated through a dedicated meta-metaanalysis.
RESULTS: sixteen reviews met the inclusion criteria, nine of them with meta-analysis. The pooled incidence among critically ill patients was 11.3% (95% CI 9.2-13.9), strongly influenced by diagnostic variability and the limited use of bronchoalveolar lavage during the pandemic. Overall mortality reached 51.6% (IQR 48.3-54.5), and CAPA tripled the risk of death compared with non-CAPA patients (OR 3.08; 95% CI 2.73-3.49). Consistent risk factors identified across meta-analyses included advanced age (OR 1.05 per year), chronic obstructive pulmonary disease (OR 1.98), type 2 diabetes mellitus (OR 1.25), systemic corticosteroid exposure (OR 1.72), and IL-6 inhibitors (OR 2.32).
DISCUSSION AND CONCLUSIONS: the marked heterogeneity observed across studies highlights the urgent need for harmonised and clinically applicable diagnostic criteria. CAPA remains an underdiagnosed condition associated with substantial mortality, underscoring the importance of early recognition strategies and improved diagnostic availability to guide timely management in high-risk patients.